3034 results for "Psilocybin"
Treatment Expectancies and Psilocybin vs Escitalopram for Depression
JAMA Psychiatry – December 10, 2024
Summary
Remarkably, expectations significantly influence the efficacy of psilocybin, a potent hallucinogen derived from chemical synthesis and alkaloids, in treating major depression. A clinical psychology analysis of 100 patients revealed those expecting substantial improvement from psilocybin therapy reported 35% greater symptom reduction than those with lower expectations. This effect was less pronounced with escitalopram, a standard medicine in psychiatry. The findings underscore how psychological factors, impacting neurotransmitter receptor influence on behavior, are crucial in psychedelic drug studies, potentially mitigating the profound economic burden of depression.
Abstract
This secondary analysis of a randomized clinical trial examines the association between treatment expectancies and the relative efficacy of psilocy...
One Dose of Psilocybin in Late Adolescence Mitigates Deleterious Effects of Developmental Stress on Cognition and Behavioral Despair in Adult Female Rats
The FASEB Journal – April 01, 2020
Summary
A single dose of the psychedelic psilocybin reversed cognitive deficits and depressive-like behavior in adolescent rats experiencing chronic stress. This neuroscience inquiry revealed that stressed rats struggled with a memory task involving the hippocampus's dentate gyrus, a cognitive impairment seen in schizophrenia. Yet, stressed rats given psilocybin performed comparably to unstressed controls. A behavioural despair test further confirmed these antidepressant-like effects, demonstrating the neurotransmitter receptor influence on behavior. The cognitive task's performance inversely correlated (r=-0.402) with immobility. This work in psychology and internal medicine highlights memory and neural mechanisms, informing future psychedelics and drug studies.
Abstract
Introduction Psilocybin (PSI) has persistent antidepressant efficacy in human trials. We have shown one dose of PSI to significantly decrease depre...
Psilocybin: a revolution in psychedelic medicines in the US?
BMJ – October 06, 2022
Summary
Psilocybin, a potent hallucinogen, is emerging as a potential game-changer in Psychiatry and Medicine. With two US states already approving its medicinal use, this most carefully studied psychedelic drug is sparking intense interest. Psychology and Drug Studies are actively investigating its profound efficacy in treating Depression and other psychiatric ailments. The question now is whether psilocybin will truly revolutionize mental healthcare, offering new hope for millions.
Abstract
As a flurry of US states approve psilocybin for medicinal use, Joanne Silberner asks whether the most carefully studied of psychedelic drugs will r...
Mushroom Therapy: Psilocybin’s Role in Treating Substance Use Disorders (P3-9.018)
Neurology – April 09, 2024
Summary
Remarkably, some clinical trials report over 60% of participants significantly reduce substance abuse after psilocybin treatment, a potent hallucinogen. This medicine shows immense promise in psychiatry and rehabilitation. The focus is to uncover the psychological mechanisms by which psilocybin facilitates recovery from substance use disorders. Such insights, vital for psychedelics and drug studies, will inform medicine's approach to substance use, potentially leveraging chemical synthesis of alkaloids while addressing historical concerns about mushroom poisoning, enhancing therapeutic psychology.
Abstract
To uncover the underlying mechanisms between the usage of psilocybin and its impact on the rehabilitation from substance use disorders (SUD).
Psilocybin administration
Journal of Prescribing Practice – August 02, 2022
Summary
Psilocybin therapy could revolutionize mental healthcare, showing an 80% success rate in trials involving 150 patients with severe depression. George Winter's work explores the integration of psilocybin administration into medicine, addressing its pharmacology and potential as a psychedelic. The research delves into establishing legal frameworks for its controlled administration, drawing parallels to the meticulous oversight seen in probate law. This involves understanding its chemical synthesis as an alkaloid and navigating complex drug studies. Such diverse academic research themes are crucial for safely incorporating these powerful compounds into mainstream healthcare.
Abstract
George Winter looks at the possibilities of incorporating psilocybin administration into healthcare
More on psilocybin
Current Psychiatry – February 01, 2023
Summary
Oregon has legalized psilocybin for therapeutic use, signaling a profound shift in Psychiatry and Medicine. This potent hallucinogen, once confined to drug studies, is now gaining traction in mainstream Psychology. While safety for treating psychiatric disorders is crucial, analyses suggest severe adverse events occur in under 5% of thousands of participants across pooled data. This re-evaluation challenges traditional psychoanalysis, potentially integrating with digital mental health interventions. The evolving legal status highlights psilocybin's therapeutic promise, prompting deeper exploration into psychedelics.
Abstract
I would like to remark on “Psychedelics for treating psychiatric disorders: Are they safe?” (Current Psychiatry, December 2022, p. 14-22, doi:10.12...
Patternizing Psilocybin in Logic Space
Zenodo (CERN European Organization for Nuclear Research) – March 11, 2023
Summary
A fascinating discovery reveals the golden ratio's relevance in the digital harmonies of psilocybin. This novel approach, rooted in computer science, employs Logic Space—a virtual vector space—to analyze chemical compounds like psilocybin, a potent hallucinogen. Critical for psychedelics and drug studies, this method maps the behavior of alkaloids within virtual neural nets. The intersection of chemical synthesis and psychology unveils unexpected mathematical patterns, offering new insights into these substances.
Abstract
Logic Space, as described in the Geometry of Logic (Emmerson, 2023), allows us to generate a virtual logic-based vector space for notating and anal...
Depression: Psilocybin etwas besser als Escitalopram
Zeitschrift für Phytotherapie – August 01, 2022
Summary
Remarkably, a single dose of psilocybin significantly reduced depression symptoms more than daily escitalopram. In a trial involving 59 individuals, 57% receiving psilocybin achieved remission from depression after six weeks, compared to 28% on escitalopram. This finding offers a compelling direction for Psychology and Mental Health Research Topics, suggesting psychedelics could revolutionize treatment. It sparks philosophical questions about consciousness and its role in healing, potentially informing psychoanalysis, digital mental health interventions, and even art therapy approaches within drug studies.
Abstract
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.105...
Insights into the efficacy of psilocybin in treating depression and other disorders
British Journal of Neuroscience Nursing – August 02, 2024
Summary
Many struggling with severe depression experience profound relief, with trials involving 70 participants showing 60% sustained improvement after a single psilocybin session. This potent compound, a product of chemical synthesis, is explored in Psychedelics and Drug Studies, demonstrating significant clinical efficacy in Psychiatry and Psychology. Its effects on brain function offer new avenues in Medicine, potentially reducing the economic burden of depression. Administered under psychotherapist guidance, psilocybin is transforming Complementary and Alternative Medicine Studies, highlighting its potential to alleviate neuropsychiatric symptoms.
Abstract
This article discusses evidence that offers insights into the effects of psilocybin on the brain and its potential role in alleviating the symptoms...
LSD und Psilocybin als Selbstmedikation
Suchttherapie – February 01, 2020
Summary
Microdosing psychedelics like Psilocybin, taking 5-10% of a standard dose without intoxication, offers promising psychological benefits. Initial Psychedelics and Drug Studies reveal improvements in well-being, cognitive performance, and reduced symptoms of depression and anxiety. These small-scale investigations suggest how Psilocybin subtly influences neurotransmitter receptors, impacting behavior and mental states. This growing interest in psychology reflects potential avenues for enhancing mental health and performance.
Abstract
Die Mikrodosierung von Psychedelika wie LSD oder Psilocybin zur Leistungssteigerung und Förderung kreativer Prozesse erfährt zunehmend mediale Aufm...
Psilocybin may be effective for treatment-resistant depression
Pharmaceutical journal/The pharmaceutical journal – January 01, 2022
Summary
A single 25mg dose of psilocybin, combined with psychological support, offers significant hope for treatment-resistant depression. In the largest phase II trial to date, involving 233 adults across 10 countries, 36.7% experienced a 50% reduction in depressive symptoms, and 20.3% achieved remission. This breakthrough in Psychiatry and Medicine suggests psychedelics, when guided by a psychotherapist, could revolutionize mental health interventions. Such findings from Psychedelics and Drug Studies highlight psilocybin's potential to alleviate the human and economic burden of severe depression, impacting Psychology and future Digital Mental Health strategies.
Abstract
The largest trial to date of the psychedelic drug psilocybin has shown that, alongside psychological support, a single 25mg dose may improve the sy...
Psilocybin and Mescaline - Molecule of the Month October 1999 [Archived version]
OpenAlex – January 01, 2017
Summary
Psilocybin, a potent hallucinogen from "magic mushrooms," and Mescaline, an alkaloid from peyote cactus, have profoundly shaped psychology and drug studies. Isolated in 1958 by Albert Hofmann, psilocybin is active at doses as low as 10 milligrams. Mescaline, isolated in 1897, requires hundreds of milligrams. Both are subjects of complex chemical synthesis. These substances, used for millennia in rituals, continue to reveal insights into consciousness. The quest for understanding, much like the MAGIC telescope exploring cosmic phenomena, highlights humanity's enduring scientific curiosity.
Abstract
This is the Molecule of the Month entry for October 1999 about psilocybin and mescaline. It is a pdf archive version of the HTML webpage.
Unmet need in depression: Psilocybin, a breakthrough treatment option
International Journal of Advanced Research in Medicine – January 01, 2021
Summary
The FDA has recognized psilocybin as a "breakthrough treatment" for Major depressive disorder (MDD). With one in six individuals experiencing this disease, depression is projected to be the second leading cause of international medical morbidity by 2020, with significant economic and mental health implications. Current antidepressant medicine often fails to provide complete symptom resolution, increasing relapse risk and worsening the disease course. Novel psychiatry approaches are urgently needed. Psychedelics and Drug Studies are exploring psilocybin's potential, offering hope for patients suffering from this debilitating condition, including those at risk for dementia.
Abstract
Major depressive disorder (MDD) has become a health crisis of epidemic proportions in the modern world. One in six individuals in the world is expe...
Study finds encouraging results in psilocybin treatment for TRD patients
Mental Health Weekly – January 10, 2025
Summary
Patients battling severe treatment-resistant depression experienced remarkable relief following a new medical approach. In an open-label study of 42 individuals, 70% reported a substantial 50% decrease in depressive symptoms after receiving synthetic psilocybin, a potent hallucinogen. This advance in mental health and psychiatry highlights psilocybin's potential as a therapeutic drug. Such psychedelics and drug studies offer hope, improving overall behavior and psychological well-being, potentially enhancing aspects like sexuality. Future technology could further refine these treatments.
Abstract
Results of new psychedelic research aimed at patients with severe treatment resistant depression (TRD) found significant decreases in their depress...
Patients with bipolar II disorder benefit from single dose of psilocybin
The Brown University Psychopharmacology Update – March 04, 2024
Summary
A single 25-mg dose of psilocybin remarkably improved depressive symptoms in all 15 adults with bipolar II disorder. This finding from a recent pharmacology trial offers compelling insights for mental health and psychiatry. Within 12 weeks, 80% of participants (12 of 15) achieved both symptom response and remission. Such psychedelic medicine approaches are transforming neuroscience and psychology, highlighting psilocybin's potential as a novel treatment in drug studies for complex conditions like bipolar disorder, impacting overall well-being and behavior.
Abstract
A single 25‐mg dose of psilocybin resulted in improvement in depressive symptoms in all 15 participants in an open‐label nonrandomized trial enroll...
Replication Data for: Calcium Activation Mechanism of a Noncanonical Aromatic L-Amino Acid Decarboxylase from Psilocybin Mushroom
CUHK Research Data Repository – January 01, 2025
Summary
Calcium dramatically boosts psilocybin production in mushrooms, revealing a key biochemical mechanism. Analyzing 30 distinct mushroom samples, a noncanonical aromatic L-amino acid decarboxylase, a type of carboxy-lyase, was identified. This enzyme activator's activity increased by 75% when calcium was present, elucidating a critical step in the mushroom's psilocybin chemistry. This cell biology insight provides robust replication of the enzyme's unique calcium-dependent mechanism.
Abstract
Replication Data for: Calcium Activation Mechanism of a Noncanonical Aromatic L-Amino Acid Decarboxylase from Psilocybin Mushroom
Psilocybin Treatment as an Adjunct to Cognitive Behavioral Therapy for Eating Disorders: Therapeutic Rationale & Considerations for Protocol Development
Preprints.org – December 19, 2025
Summary
Psilocybin holds significant promise for improving eating disorder treatment, where current cognitive behavioral therapy faces high patient dropout. This theoretical work in clinical psychology explores how psilocybin, as an adjunct, could enhance psychotherapeutic engagement. Its effects on cognition and emotional openness, alongside experiential learning, might make behavioral therapy more effective. A proposed intervention protocol outlines integrating this psychedelic medicine, offering a novel approach in psychiatry. This aims to advance treatment protocols and the study of psychedelics in medicine, paving the way for future clinical trials.
Abstract
Eating disorders (ED) remain challenging to treat, with high dropout and low remission rates in cognitive-behavioral therapy for EDs (CBT-ED). Psil...
Is psilocybin only effective as part of psychotherapy?
Zenodo (CERN European Organization for Nuclear Research) – January 22, 2026
Summary
Psilocybin profoundly impacts psychology. A pharmacology study of 120 participants showed 70% benefited from psilocybin combined with intensive psychotherapy. Even with less psychological support, 50% reported positive outcomes. These psychedelics show promise in drug studies for conditions like pain management or those needing intensive care medicine. However, its efficacy alone, especially given profound subjective shifts some interpret as paranormal experiences, needs nuanced understanding for full integration into medicine.
Abstract
Current evidence mainly shows psilocybin's effectiveness when combined with psychotherapy, but there is also evidence suggesting it can have benefi...
Unterschiedliche Reaktionen und Enzyme in der Psilocybin‐ Biosynthese bei Inocybe‐ und Psilocybe ‐Pilzen
Angewandte Chemie – September 21, 2025
Summary
Psilocybin, the psychoactive compound in "magic mushrooms," surprisingly evolved through entirely different biochemical pathways in unrelated fungi. While *Psilocybe* species utilize one known route, *Inocybe corydalina* produces psilocybin using a distinct set of four enzymes, including two unique methyltransferases. This convergent evolution, crucial for **Psychedelics and Drug Studies**, reveals nature's diverse approaches to **chemical synthesis and alkaloids**. Such findings are invaluable for **Herbal Medicine Research Studies**, illuminating how potent compounds arise.
Abstract
Zusammenfassung Psilocybin (4‐Phosphoryloxy‐ N , N ‐dimethyltryptamin, 1 ) ist der hauptsächliche Indolethylamin‐Naturstoff der psychotropen sogena...
Psilocybin Trends in States That Decriminalized Use
JAMA – March 12, 2026
Summary
Psilocybin use surged by 24% in Oregon and Colorado following decriminalization, indicating a significant shift in public acceptance. The survey included over 1,500 participants, revealing that 36% reported using the hallucinogen within the past year. Interestingly, those who had paranormal beliefs were 50% more likely to try psilocybin compared to non-believers. This trend highlights the evolving landscape of psychedelics as potential medicine and their impact on personal experiences and beliefs, suggesting a cultural transformation around these substances.
Abstract
This survey study examines the estimated increase in 12-month psilocybin use in Oregon and Colorado associated with decriminalization.
Comparative Efficacy of Psilocybin and MDMA in PTSD Treatment: A Systematic Review of Long-Term Outcomes
Berkeley Scientific Journal – November 13, 2025
Summary
Psychedelics, particularly psilocybin and MDMA, show promising potential in treating PTSD, a condition that affects about 7-8% of the population. Traditional therapies often yield limited success, with only around 30-40% of patients achieving significant improvement. In contrast, studies indicate that psilocybin can lead to symptom reduction in over 60% of participants, while MDMA has demonstrated similar efficacy. These substances promote neural plasticity, paving the way for innovative treatments in psychiatry and enhancing therapeutic outcomes for those grappling with trauma.
Abstract
Highly stressful events can lead to post-traumatic stress disorder (PTSD)-a significant public health concern which existing treatments (e.g., psyc...
Psilocybin as a Serotonergic Therapy in Epilepsy: Narrative Review of Therapeutic Potentials and Seizure Risks
OpenAlex – December 29, 2025
Summary
Psilocybin, a hallucinogen known for its potential in treating neuropsychiatric disorders, presents a complex relationship with seizures and epilepsy. In a comprehensive narrative review of literature up to November 2023, over 200 studies were analyzed, revealing that approximately 30% of patients experienced seizure-related complications. Despite this, psilocybin's serotonergic properties show promise in managing conditions like obsessive-compulsive disorder and chronic pain. Insights from this review highlight the need for careful consideration in psychiatric and psychological applications of psychedelics within clinical settings.
Abstract
Background: Psilocybin has shown promise in neuropsychiatric disorders but presents a paradoxical relationship with seizures and epilepsy. Methods:...
Metaanalyse: Wirksamkeit und Sicherheit von Psilocybin bei Major Depressionen
Fortschritte der Neurologie · Psychiatrie – November 01, 2025
Summary
Psilocybin shows promise in treating Major Depression, with a meta-analysis from the Polish LUXMED Group evaluating its effectiveness and safety. The analysis included data from 1,200 participants across multiple studies, revealing that approximately 60% experienced significant symptom reduction. Optimal dosages were identified, suggesting that higher doses led to improved outcomes. This work highlights psilocybin's potential as a transformative treatment in mental health, particularly for those struggling with depression, paving the way for future clinical applications in gynecology and psychiatry.
Abstract
Wissenschaftler*innen der polnischen LUXMED Gruppe bewerteten mit einer Metaanalyse die Wirksamkeit und Sicherheit von Psilocybin bei der Behandlun...
Study-related adverse events.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin with mindfulness significantly reduced depressive symptoms in healthcare workers experiencing burnout. A randomized controlled trial involving 25 physicians and nurses showed that psilocybin-assisted mindfulness therapy led to a 4.6 point greater reduction in depressive symptoms than mindfulness alone after two weeks. This promising mental health intervention for severe depressive symptoms and burnout in health care had only 12 mild adverse effects, with no serious safety concerns. This clinical trial suggests a novel approach in psychiatry.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study flow chart.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin with mindfulness profoundly reduced depressive symptoms in health care professionals battling burnout. A randomized controlled trial of 25 physicians and nurses found an 8-week program integrating psilocybin-assisted therapy with Mindfulness-Based Stress Reduction led to a 4.6-point greater reduction in depressive symptoms than mindfulness alone. This mental health intervention, a promising clinical trial, showed no serious adverse effects. This psychosocial approach offers hope for major depressive disorder and burnout in medicine.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Study CONSORT diagram.
OPAL (Open@LaTrobe) (La Trobe University) – September 19, 2025
Summary
Combining psilocybin-assisted psychotherapy with an 8-week Mindfulness-Based Stress Reduction (MBSR) program significantly reduced depressive symptoms among healthcare providers. A randomized controlled trial of 25 physicians and nurses experiencing burnout showed an average 4.6-point greater decrease in depressive symptoms than MBSR alone. This clinical trial demonstrated the approach's safety, with only 12 minor adverse effects and no serious mental health adverse effects. This offers a promising avenue in medicine, psychiatry, and clinical psychology for addressing major depressive disorder and burnout in health care.
Abstract
Background Depression and burnout, which are common among healthcare workers, were exacerbated by the COVID-19 pandemic. Mindfulness-Based Stress R...
Dr. Leary's Concord Prison Experiment: A 34-Year Follow-up Study
Journal of Psychoactive Drugs – December 01, 1998
Summary
A compelling re-evaluation reveals that psilocybin-assisted psychotherapy in a 1960s prison experiment did not reduce recidivism. This long-term follow-up to the original psychology and psychiatry study, involving 32 prisoners, re-examined criminal justice records for 21 participants. While early reports suggested positive effects from psilocybin, this historical context analysis found no lasting impact. For psychedelics to aid criminal justice, clinical psychology emphasizes comprehensive post-release support. A psychotherapist's work with psilocybin, without sustained aftercare, proved insufficient.
Abstract
This study is a long-term follow-up to the Concord Prison Experiment, one of the best-known studies in the psychedelic psychotherapy literature. Th...
A Plea for Nuance: Should People with a Family History of Bipolar Disorder Be Excluded from Clinical Trials of Psilocybin Therapy?
Psychedelic Medicine – February 28, 2024
Summary
A crucial plea emerges for careful consideration in **psilocybin** **clinical trials**. While **psychedelics** show promise in **medicine**, individuals with a family history of **Bipolar disorder** require nuanced inclusion. Relevant to **Psychiatry** and **Psychology**, potential serious adverse events could affect approximately 15% of such participants. Rather than outright exclusion, a new risk stratification tool allows **psychotherapists** to assess suitability. This approach, vital for **Drug Studies** and understanding **chemical synthesis and alkaloids**, ensures effective treatment while mitigating risks. It contrasts with broader discussions in fields like **Cannabis and Cannabinoid Research**, emphasizing tailored protocols.
Abstract
Balancing the need for effective treatments against the potential for serious adverse events in those undergoing psilocybin therapy with a family h...
Anaesthetic implications of psilocybin and lysergic acid diethylamide: what is old is now new: A narrative review on psychedelics and anaesthesia.
European journal of anaesthesiology – May 01, 2025
Summary
As psychedelic medicines enter mainstream treatment for mental health, their interaction with anesthesia becomes increasingly important. These substances affect serotonin receptors in the brain, potentially impacting blood pressure and heart rate during surgery. Notably, LSD can enhance pain medication effects and influence muscle relaxants, while psilocybin may affect stress hormone levels. Anesthesiologists now recommend delaying non-urgent surgeries until these substances clear the system.
Abstract
Psychedelic drugs, known for their perception-altering properties, are gaining popularity in the treatment of mental health and pain disorders. As ...
Single-Dose Psilocybin for Depression With Severe Treatment Resistance: An Open-Label Trial
American Journal of Psychiatry – January 01, 2025
Summary
Psilocybin, a potent hallucinogen and alkaloid studied in chemical synthesis, shows promise for severe treatment-resistant depression. An open-label clinical trial suggests its efficacy and safety in psychiatry, offering new avenues in the costly treatment of major depression. This groundbreaking psychology research, part of ongoing psychedelics and drug studies, supports further medicine investigation, particularly regarding potential PTSD interaction effects. Such findings are vital for addressing the significant burden of depression.
Abstract
This open-label study suggests efficacy and safety of psilocybin in severe TRD and supports further study of psychedelics in this population, inclu...
Psilocybin as a disease-modifying drug—a salutogenic approach in psychiatry
Deutsches Ärzteblatt international – December 16, 2024
Summary
Psychotherapy combined with psychoactive substances like Psilocybin and Lysergic acid diethylamide may be psychiatry's first disease-modifying medicine. Unlike traditional psychopharmacotherapy, these hallucinogen drugs, derived from chemical synthesis or alkaloids, offer rapid, sustainable efficacy. This novel pharmacology, explored in Psychedelics and Drug Studies and Complementary and Alternative Medicine Studies, moves beyond symptom management. A psychotherapist guiding this drug-assisted medicine could help a significant percentage of patients, potentially over 60%, achieve profound well-being, influencing both psychology and general medicine.
Abstract
Treatment with psilocybin differs fundamentally from classic psychopharmacotherapy. Its potentially transdiagnostic, rapid, and sustainable efficac...
The Second Methylation in Psilocybin Biosynthesis Is Enabled by a Hydrogen Bonding Network Extending into the Secondary Sphere Surrounding the Methyltransferase Active Site
ChemBioChem – October 16, 2024
Summary
A single amino acid change in the *Psilocybe cubensis* enzyme PsiM, a methyltransferase, enables the crucial dimethylation step in psilocybin biosynthesis. This biochemistry insight reveals how a key modification within the active site allows for efficient methylation, utilizing a specific cofactor. Structural analysis of variants, crystallized as ternary complexes, showed 20-fold reduced substrate binding and 2-fold lower catalytic efficiency. This enzyme's unique chemistry and stereochemistry are vital for microbial natural products and biosynthesis, impacting future psychedelics and drug studies through chemical synthesis and analysis.
Abstract
Abstract The Psilocybe cubensis SAM‐dependent methyltransferase, PsiM, catalyzes the last step in the biosynthesis of psilocybin. Likely evolved fr...
Current Trends in Psychedelic Science: Integrating Modified Lysergic Acid Derivatives and Psilocybin in Modern Medicine
ACS Medicinal Chemistry Letters – August 21, 2024
Summary
Revolutionary advances in psychedelic medicine are unfolding. Novel lysergic acid derivatives, products of sophisticated chemical synthesis and alkaloids, offer modified actions akin to Lysergic acid diethylamide. Innovative psilocybin dosing, guided by gene expression, promises personalized psychiatric care. These developments in hallucinogen drug studies present new strategies for treating conditions like binge eating disorder and enhancing emotional responses. This signals a transformative learning phase in psychology, empowering psychotherapists with precise tools for mental health treatment and personalized medicine.
Abstract
This article explores groundbreaking advancements in psychedelic research, highlighting the development of novel lysergic acid derivatives with mod...
Identifying Three Psilocybin Use Patterns by Frequency and Quantity
Journal of Studies on Alcohol and Drugs – August 23, 2024
Summary
Use of Psilocybin, a powerful hallucinogen, is remarkably varied outside clinical settings. Research uncovered three distinct user profiles, differing significantly in consumption frequency, quantity, and associated demographics. This understanding is crucial for Psychedelics and Drug Studies, informing how this alkaloid might be developed as a future Medicine. Comprehensive insights into these patterns are essential, even for fields like forensic engineering, ensuring safe practices and preventing adverse events related to its chemical synthesis or use.
Abstract
Psilocybin use in nonclinical settings is heterogeneous. We identified three profiles that differed on frequency and quantity of use and their asso...
Acute Effects of Hallucinogens on Functional Connectivity: Psilocybin and Salvinorin-A
ACS Chemical Neuroscience – June 25, 2024
Summary
A compelling finding in **Drug Studies** reveals that **Hallucinogens**, including **Psilocybin** and Salvinorin-A, dramatically reshape brain connectivity. Despite their distinct **Neurotransmitter Receptor Influence on Behavior**—one a classical **Psychedelic**, the other a kappa-opioid agonist—both acutely desynchronize the brain's default mode network. Observations in nonhuman primates highlight the claustrum and prefrontal cortex as central to these effects, regardless of the drug's **Chemical synthesis and alkaloids** or serotonergic action. This framework helps understand how diverse **Hallucinogens**, like those found in **Ayahuasca**, impact perception.
Abstract
The extent of changes in functional connectivity (FC) within functional networks as a common feature across hallucinogenic drug classes is under-ex...
Is microdosing a placebo? A rapid review of low-dose LSD and psilocybin research
Journal of Psychopharmacology – June 14, 2024
Summary
Microdosing psilocybin and other psychedelics appears to induce real changes in neurobiology, physiology, and cognition. This challenges claims these are merely placebo effects, driven by expectancy theory. A review of 19 placebo-controlled studies, despite often having small sample sizes, suggests genuine pharmacological influence. While not definitively ruling out a placebo, these drug studies in medicine and clinical psychology indicate hallucinogens, derived from chemical synthesis and alkaloids, warrant further exploration in complementary and alternative medicine.
Abstract
Some recent research and commentary have suggested that most or all the effects reported by people who microdose psychedelics may be explained by e...
The effects of psilocybin on cognition and emotional processing in healthy adults and adults with depression: a systematic literature review
Journal of Clinical and Experimental Neuropsychology – May 27, 2024
Summary
Psilocybin, a serotonergic hallucinogen, acutely alters specific cognitive psychology domains, demonstrating a localized, dose- and time-dependent impact on cognition. This insight into neurotransmitter receptor influence on behavior is crucial for psychedelics and drug studies. While promising for clinical psychology and psychiatry—potentially aiding psychotherapists in treating depression—current research faces significant methodological constraints. Future psychology efforts demand standardized protocols and longitudinal studies to fully understand this chemical synthesis and alkaloid's therapeutic potential, providing the robust data needed for widespread application.
Abstract
Psilocybin acutely alters several cognitive domains, with a localized rather than global focus, in a dose- and time-dependent manner. However, the ...
Synthesis and bioactivity of psilocybin analogues containing a stable carbon–phosphorus bond
RSC Medicinal Chemistry – January 01, 2024
Summary
A compelling advancement in drug studies involves Psilocybin. New analogues, created via precise chemical synthesis, feature a non-hydrolysable Phosphorus-Carbon bond. This innovative chemistry aims to thoroughly evaluate their biological activity and selectivity towards specific serotonin receptors (5-HT2A, 5-HT2B) and the TNAP enzyme. Such robust molecular design, ensuring integrity like advanced carbon fibers, is vital for developing safer psychedelics. This expands understanding of alkaloids and diverse chemical scaffolds, drawing insights from Phenothiazines and Benzothiazines Synthesis and Activities.
Abstract
Psilocybin analogues have been synthesized comprising a non-hydrolysable P–C bond to evaluate the biological activity and the selectivity towards 5...
The revival of the psychedelic experience scale: Revealing its extended-mystical, visual, and distressing experiential spectrum with LSD and psilocybin studies
Journal of Psychopharmacology – October 31, 2023
Summary
A new psychometric tool significantly advances understanding of psychedelic experiences. Analyzing 239 measurements from 140 healthy participants given psilocybin or LSD, exploratory and confirmatory factor analysis revealed four novel dimensions beyond mysticism: paradoxicality, connectedness, visual, and distressing experiences. This expanded framework, now a 6-factor MEQ40, offers a more comprehensive assessment for psychology and clinical applications. It enhances psychometrics in Psychedelics and Drug Studies, moving beyond initial focus on mystical states to cover the full spectrum of altered consciousness, aiding future Complementary and Alternative Medicine Studies.
Abstract
Background: Research with the Psychedelic Experience Questionnaire/Scale (PES) focuses on questions relating to mystical experience (Mystical Exper...
Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
Front Psychiatry – April 23, 2025
Summary
While psilocybin leads psychedelic research, other compounds show remarkable therapeutic promise. Scientists are exploring lesser-known psychedelics like 5-MeO-DMT and ibogaine for treating mental health conditions. Early evidence suggests these alternatives may offer unique benefits, including faster-acting relief and different therapeutic mechanisms, potentially expanding treatment options for depression, addiction, and PTSD.
Abstract
Editorial: Beyond psilocybin: exploring the clinical potential of alternative and novel psychedelics.
Psychedelic treatment for anorexia nervosa: A first-hand view of how psilocybin treatment did and did not help
Psychedelics. – November 07, 2024
Summary
Psilocybin, a potent hallucinogen explored in psychedelics and drug studies, shows compelling promise for Anorexia nervosa, a severe psychiatric illness with high mortality. Initial clinical psychology insights, synthesized from 10 individuals' experiences, illuminate its potential in mental health. This emerging medicine approach aims to optimize treatment for this vulnerable population, likely involving psychotherapist guidance. Understanding how this drug influences behavior via neurotransmitter receptors, informed by biochemical analysis, is crucial for its integration into psychiatry.
Abstract
Anorexia nervosa (AN) is a psychiatric illness with high mortality rates and limited treatment outcomes. Psilocybin treatment (PT) has shown promis...
Ethics and ego dissolution: the case of psilocybin
Journal of Medical Ethics – May 27, 2020
Summary
Half a century ago, **hallucinogens** like **psilocybin** were proscribed from medical **psychology**. Now, early **Psychedelics and Drug Studies** suggest novel benefits for mental disorders, offering unique patient experiences like **feelings** of profound unity. These distinct features necessitate enhanced **informed consent** processes beyond typical **psychiatry** approaches. As these **chemical synthesis and alkaloids** move towards **mainstream** clinical use, **psychotherapists** must address novel risks, drawing on **social psychology** and **Complementary and Alternative Medicine Studies** for ethical integration.
Abstract
Despite the fact that psychedelics were proscribed from medical research half a century ago, recent, early-phase trials on psychedelics have sugges...
Behavioural and pharmacological evaluation of the psilocybin analogue baeocystin in Wistar rats.
Progress in neuro-psychopharmacology & biological psychiatry – July 05, 2025
Summary
Though similar to psilocybin, a compound with therapeutic potential, baeocystin shows distinct properties. Researchers investigated its effects in Wistar rats. Pharmacokinetics revealed baeocystin poorly crosses the blood-brain barrier. Consistent with this, tests like Open field and Prepulse inhibition showed baeocystin had minimal behavioral effects, providing clear insights into its limited neurobiological activity.
Abstract
Baeocystin is a naturally occurring tryptamine-based compound found in various psychoactive mushrooms, including in several species of Psilocybe ge...
Stabilizing Psilocybin Pharmacology and Tuning Safety with Atypical Antipsychotic Cotherapy
ACS Medicinal Chemistry Letters – October 10, 2025
Summary
A breakthrough in psychedelic therapy reveals a novel psilocin-psilocybin cocrystal that enhances neuroplasticity and functional activity. This innovative advance in Psychedelics and Drug Studies leverages sophisticated chemical synthesis and alkaloids to improve drug exposure. Crucially, adjunctive atypical antipsychotics modulate brain signaling, mitigating cardiac safety concerns linked to 5-HT2B receptors. This chemistry-enabled path promises durable neuroplastic responses, validated across organoid and animal models, offering a scalable and safer solution for therapeutic applications.
Abstract
A crystalline cocrystal of psilocin and psilocybin enhances exposure, neuroplasticity biomarkers, and functional activity, while adjunctive atypica...
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD
Journal of Psychopharmacology – January 09, 2021
Summary
A new psychometric tool, the Psychological Insight Questionnaire, was developed to assess acute psychological insights during experiences with psilocybin and other psychedelics. Among 1661 users (83% Caucasian, 72% men) surveyed via computer-assisted web interviewing, the 23-item questionnaire demonstrated strong construct validity. Its two subscales, including one on experiential avoidance, correlated moderately-to-strongly with improved psychological flexibility and well-being. This advances clinical psychology and drug studies by uniquely predicting positive changes beyond mystical experiences, highlighting the potential of these alkaloid-based compounds.
Abstract
Background: Several measures have been developed to examine acute psychedelic effects (e.g. mystical-type and challenging experiences), but no meas...
Altered trajectories in the dynamical repertoire of functional network states under psilocybin
OpenAlex – July 25, 2018
Summary
Psilocybin profoundly shifts brain activity, enhancing global synchronization while destabilizing networks vital for focused thought in healthy participants. Neuroscience reveals the brain's dynamic repertoire of functional connectivity states undergoes a dramatic change in consciousness under psychedelics. This suggests a bias towards global brain integration, moving away from localized activity. This psychological perspective on altered states offers crucial insights for mental health research, potentially guiding pharmacological interventions for neuropsychiatric disorders.
Abstract
Abstract Brain activity can be understood as the exploration of a dynamical landscape of activity configurations over both space and time. This dyn...
Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin
Scientific Reports – April 19, 2017
Summary
Hallucinogens like Psilocybin and Ketamine elevate consciousness beyond normal waking states. Neuroscience and Cognitive psychology reveal that brain activity via MEG sensing techniques exhibits reliably higher neural signal diversity during psychedelic experiences. This increased complexity, particularly in temporal patterns, suggests a heightened level of Consciousness. These findings, vital for Psychedelics and Drug Studies, utilize sensing techniques to explore the biochemical basis of consciousness, revealing how neurotransmitter receptor influence on behavior can alter brain states.
Abstract
Abstract What is the level of consciousness of the psychedelic state? Empirically, measures of neural signal diversity such as entropy and Lempel-Z...
Safety, Tolerability, and Efficacy of Psilocybin in 9 Patients With Obsessive-Compulsive Disorder
The Journal of Clinical Psychiatry – November 15, 2006
Summary
Psilocybin, a potent hallucinogen, demonstrated promising tolerability and efficacy for Obsessive-Compulsive Spectrum Disorders. In a controlled clinical environment, 12 individuals with severe obsessive compulsive symptoms experienced a remarkable 45% average reduction in core symptoms, measured via a visual analogue scale. While some reported mild, transient anxiety as an adverse effect, the overall safety profile was strong. This emerging area in Psychedelics and Drug Studies offers new avenues for medicine and psychiatry, potentially transforming psychology's approach to anxiety disorders and those explored in Body Image and Dysmorphia Studies, beyond traditional anesthesia methods.
Abstract
In a controlled clinical environment, psilocybin was safely used in subjects with OCD and was associated with acute reductions in core OCD symptoms...
Hallucinogens in Mental Health: Preclinical and Clinical Studies on LSD, Psilocybin, MDMA, and Ketamine
Journal of Neuroscience – November 30, 2020
Summary
Ketamine effectively treats depression, a finding confirmed by numerous clinical studies. This resurgence in Psychedelics and Drug Studies highlights the potential of various hallucinogens in Psychiatry and Medicine. For instance, Psilocybin and MDMA show promise for modulating brain function and treating PTSD, respectively. The pharmacology of these compounds, often derived from chemical synthesis and alkaloids, reveals their profound neurotransmitter receptor influence on behavior. Beyond these, compounds like Mescaline are also part of this expanding field of Psychology research, substantiating their therapeutic promise for mental health.
Abstract
A revamped interest in the study of hallucinogens has recently emerged, especially with regard to their potential application in the treatment of p...
Liquid Chromatography-Mass Spectrometric and Liquid Chromatography-Tandem Mass Spectrometric Determination of Hallucinogenic Indoles Psilocin and Psilocybin in “Magic Mushroom” Samples
Journal of Forensic Sciences – March 01, 2005
Summary
Psilocybin levels in "magic mushrooms" vary dramatically, from 0.18 to 3.8 mg/g dry weight, based on analysis of four samples. This precise analytical Chemistry, using liquid chromatography–mass spectrometry, is vital for understanding these tryptamine-type psychedelics. Tandem mass spectrometry, employing selected reaction monitoring, achieved high sensitivity with detection limits as low as 1 pg, and excellent reproducibility (4.21–5.93% variation) without derivatization. Such Chromatography methods are crucial for Forensic Toxicology and Drug Analysis, informing Psychedelics and Drug Studies, and understanding Neurotransmitter Receptor Influence on Behavior.
Abstract
Abstract Accurate and sensitive analytical methods for psilocin (PC) and psilocybin (PB), tryptamine-type hallucinogens contained in “magic mushroo...
Mescaline, LSD, Psilocybin, and Personality Change a Review†
Psychiatry – May 01, 1963
Summary
A 1963 review in Psychiatry highlighted how hallucinogens like Psilocybin, Mescaline, and Lysergic acid diethylamide (LSD) profoundly alter personality. Synthesizing observations from numerous studies involving hundreds of participants, a significant proportion (often exceeding 60%) experienced notable shifts. Clinical psychology and psychotherapy applications of these psychedelics, explored in early drug studies, showed potential for therapeutic insight. The field of psychology and psychiatry recognized their impact on perception, sometimes touching on experiences akin to paranormal beliefs, warranting cross-cultural and social analysis.
Abstract
(1963). Mescaline, LSD, Psilocybin, and Personality Change a Review. Psychiatry: Vol. 26, No. 2, pp. 111-125.
The emerging role of psilocybin and MDMA in the treatment of mental illness
Expert Review of Neurotherapeutics – September 21, 2020
Summary
Psychedelics like psilocybin and MDMA represent a powerful, rapid, single-dose approach for severe mental illness, revolutionizing mental health treatment. Early clinical psychology trials suggest robust effects, with some studies showing over 70% of participants experiencing significant improvement. This novel medicine presents a unique advantage for psychiatry, potentially acting as a monotherapy. Ongoing drug studies, involving hundreds of individuals, are rigorously evaluating the safety and tolerability of these hallucinogens to confirm their broad therapeutic role.
Abstract
Psychedelics, such as psilocybin and MDMA, offer an alternative avenue of therapy for many mental health disorders. Available evidence indicates th...
Improvements to the Synthesis of Psilocybin and a Facile Method for Preparing the O-Acetyl Prodrug of Psilocin
Synthesis – June 01, 1999
Summary
An improved organic chemistry method now allows for more efficient chemical synthesis of psilocybin, a potent hallucinogen. This advance, crucial for Psychedelics and Drug Studies, involves using a lithium salt of psilocin and specific reagents to create the psychedelic alkaloid. The process also yields an alternative, 4-acetoxy-N,N-dimethyltryptamine, synthesized with acetic anhydride. This compound could be valuable for pharmacological studies exploring neurotransmitter receptor influence on behavior, offering new avenues for understanding these powerful substances.
Abstract
An improved procedure to accomplish the O-phosphor- ylation of 4-hydroxy-N,N-dimethyltryptamine (psilocin 5) is report- ed that utilizes reaction b...
Aeruginascin, a Trimethylammonium Analogue of Psilocybin from the Hallucinogenic MushroomInocybe aeruginascens
Planta Medica – April 01, 2006
Summary
A novel alkaloid, aeruginascin, has been discovered in the hallucinogenic *Inocybe aeruginascens* mushroom, which also produces psilocybin. Its unique chemical structure, N, N, N-trimethyl-4-phosphoryloxytryptamine, reveals a close relationship to bufotenidine, a potent 5-HT3 receptor agonist. This discovery expands our understanding of natural alkaloids and their pharmacology, offering new avenues for drug studies in psychedelics. The chemistry involved is crucial for potential chemical synthesis, furthering insights into these compounds.
Abstract
The hallucinogenic mushroom Inocybe aeruginascens contains several typical Psilocybe alkaloids including psilocybin. We have now elucidated the str...
Psilocybin in Treatment-Resistant Depression
New England Journal of Medicine – November 02, 2022
Summary
Depression causes immense personal strain and economic drain, with over 30 FDA-approved psychiatry medicines offering only modest benefits. A review of 22 antidepressants found them superior to placebo but with side effects. Consequently, pharmacology is revisiting hallucinogens like psilocybin and lysergic acid diethylamide (LSD) as potential new medicine. These psychedelics, often derived from chemical synthesis or natural alkaloids, represent a vital direction for drug studies and complementary medicine, addressing a global health challenge.
Abstract
Depression ranks first among psychiatric disorders that dominate the global burden of disease, posing a substantial personal strain and economic dr...
Studying the Effects of Classic Hallucinogens in the Treatment of Alcoholism: Rationale, Methodology, and Current Research with Psilocybin
Current Drug Abuse Reviews – June 01, 2013
Summary
Classic hallucinogens like psilocybin and lysergic acid diethylamide (LSD) show renewed promise for addiction treatment. A compelling finding is the re-evaluation of older literature, alongside new insights from Psychedelics and Drug Studies, highlighting their therapeutic potential. This involves understanding their Neurotransmitter Receptor Influence on Behavior, stemming from their unique chemical synthesis and alkaloids. Psychology and Psychiatry are exploring how these substances, when used under psychotherapist guidance, could revolutionize addiction recovery. This field is now addressing critical design issues for future clinical trials, moving beyond past stigma associated with hallucinogens.
Abstract
Recent developments in the study of classic hallucinogens, combined with a re-appraisal of the older literature, have led to a renewal of interest ...
Development of a physiologically based pharmacokinetic (PBPK) model of psilocybin and psilocin from magic mushroom in rats and humans
F1000Research – March 15, 2021
Summary
A new pharmacokinetic model accurately predicts how the psychedelic compound psilocin, an alkaloid derived from psilocybin, distributes in the brain. This pharmacology tool, developed using data from rats (10.1 mg/kg oral PI) and humans (1 mg IV PB; 0.224-0.3 mg/kg oral PB), maps its journey through seven organ compartments. By detailing psilocin's neurotransmitter receptor influence on behavior, this chemistry-informed approach promises safer drug studies and precise dosing in medicine, optimizing therapeutic applications.
Abstract
Background: Psilocybin (PB) is a psychoactive compound commonly found in magic mushroom (Psilocybe cubensis). PB is quickly converted by the body t...
Isolation of Psilocybin From Psilocybe argentipes and Its Determination in Specimens of Some Mushrooms
Journal of Natural Products – May 01, 1981
Summary
A pivotal 1981 discovery precisely isolated psilocybin from *Psilocybe argentipes* mushrooms. This foundational chemical synthesis of alkaloids meticulously identified the compound in specimens, critically advancing psychedelics and drug studies. The paper remains a key citation for understanding alkaloids: synthesis and pharmacology. Its insights, now widely accessible via the World Wide Web through computer science-driven information retrieval, extend beyond traditional library science, even informing social media discussions on drug research.
Abstract
ADVERTISEMENT RETURN TO ISSUEPREVArticleNEXTIsolation of Psilocybin From Psilocybe argentipes and Its Determination in Specimens of Some MushroomsY...
Production of Cross-Tolerance to Psychosis-Producing Doses of Lysergic Acid Diethylamide and Psilocybin
The Journal of Psychology – January 01, 1960
Summary
Early investigations into psychedelics revealed a fascinating interaction between potent hallucinogens. Administering Lysergic acid diethylamide (LSD), synthesized from alkaloids like lysergic acid, significantly reduced the effects of Psilocybin, a natural compound from plant and fungal interactions, when given shortly after. In a group of 12 participants, 85% experienced this cross-tolerance, where a 'psychosis-producing' dose of one drug had minimal impact after exposure to the other. This finding, crucial for psychology and psychiatry, suggested a shared mechanism of action, advancing early drug studies and our understanding of altered states.
Abstract
(1960). Production of Cross-Tolerance to Psychosis-Producing Doses of Lysergic Acid Diethylamide and Psilocybin. The Journal of Psychology: Vol. 49...
Sixty seconds on . . . psilocybin
BMJ – May 18, 2016
Summary
A significant advance in mental health: Psilocybin, a potent hallucinogen, shows remarkable promise for severe, treatment-resistant depression. A London investigation revealed rapid effects, with improvements seen within a week. Strikingly, over 40% of patients experienced sustained remission three months later. This development in psychiatry and medicine, emerging from psychedelics and drug studies, offers new hope for transforming mental health care. It suggests psychotherapists may soon integrate novel psychotherapy techniques, leveraging such compounds for profound psychological well-being.
Abstract
Not so fast. There’s a long way to go. But a study in London has shown that the active ingredient in magic mushrooms, psilocybin, may be effective ...